Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 46 | 63 | +17 |
| Shares | 4.40M | 8.19M | +3.79M (+86.2%) |
| Value | $8.40M | $21.0M | +$12.6M (+149.5%) |
New holders (22)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
Sold out (5)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Virtu Financial LLC | 34,276 | $64.0K |
| PFG Investments, LLC | 20,730 | $39.0K |
| Y-Intercept (Hong Kong) Ltd | 18,818 | $35.4K |
| Group One Trading, L.P. | 656 | $1.23K |
| SRS Capital Advisors, Inc. | 39 | $74 |